Premium
The respiratory effects of oral ethyl loflazepate in volunteers.
Author(s) -
Fazackerley EJ,
Randall NP,
Pleuvry BJ,
Bradbrook I,
Mawer GE
Publication year - 1987
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1987.tb03027.x
Subject(s) - metabolite , volunteer , placebo , respiratory system , respiration , active metabolite , oral administration , pharmacology , chemistry , plasma levels , medicine , biology , alternative medicine , pathology , anatomy , agronomy
A volunteer study was undertaken to assess the respiratory effects of ethyl loflazepate, a new benzodiazepine, and to correlate these with plasma concentrations of the active metabolites. Twelve volunteers were given placebo, 2 mg ethyl loflazepate, and 6 mg ethyl loflazepate on separate occasions. Respiration and plasma metabolite levels were assessed hourly for 8 h and at 24 h. The 6 mg ethyl loflazepate treatment produced a significant decrease (P less than 0.02) in the ventilatory response to carbon dioxide at 5 h. However this did not equate with a peak in plasma metabolite concentrations which were maintained at a plateau level from 4 to 24 h.